A Pilot Open-Label Single-Dose Study Using Intravenous Micellar Paclitaxel for Patients With Severe Psoriasis
Paclitaxel is an antiangiogenic chemotherapeutic drug approved by the FDA for use in cancer.
There is anecdotal evidence that some patients with cancer and concomitant psoriasis have
shown improvement in their skin while receiving paclitaxel for cancer. Angiotech
Pharmaceutical, Inc., the company with commercial rights over non-cancer uses of paclitaxel,
has data that suggests paclitaxel demonstrates anti-inflammatory and immunomodulatory
properties, in addition to the better known antiangiogenic and antiproliferative effects
attributed to this compound. In this pilot open-label single-dose study, we initially
treated patients with severe refractory psoriasis using intravenous Micellar Paclitaxel (75
mg/m(2) every 4 weeks) for six months. Because this dosing regimen was well tolerated and
because the dosing interval seemed too long, we now propose to treat patients with
intravenous Micellar Paclitaxel at the adjusted dose of 37.5 mg/m(2) every 2 weeks.
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
United States: Federal Government
|National Cancer Institute (NCI)||Bethesda, Maryland 20892|